Searched for
REGENERON
A 15-year-old from Ontario built a bionic underwater “robot turtle” that detects what is quietly killing our seas and just won $50,000 for itA young innovator has created BURT, a robotic turtle that moves quietly underwater. This AI-powered machine mimics natural swimming to obse...- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
- US stocks today: Nasdaq falls as technology stocks slide, Treasury yields climbUS stocks closed mixed as Nasdaq slipped due to profit booking and rising Treasury yields, while Dow edged higher. Oil prices surged on sup...
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiativeRegeneron will reduce prices for its drugs on Medicaid. A cholesterol drug, Praluent, will be available for USD 225 on Trump's discounted d...
- Global Markets | Australian shares slide as US-Iran talks fail, risk appetite soursAustralian shares declined as collapsed U.S.-Iran peace talks and a U.S. blockade of Iranian ports soured market sentiment. The S&P/ASX 200...
- Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA dataSouth San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after a decline in c...
- Regeneron to rescue 23andMe from bankruptcy in $256 million deal — but who really owns your genetic data now and what happens to your DNA privacy?Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and what happens to ...
- Biocon Biologics secures market entry for Yesafili in USBiocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili...
- EU approves Sanofi's Dupixent for 'smoker's lungs'Sanofi and Regeneron received EU approval for broader use of Dupixent in treating chronic obstructive pulmonary disease (COPD), a significa...
- Five Indian-American teenagers selected as finalists of prestigious science and maths competition in USAmong them, the five Indian American include Siddhu Pachipala from Texas, Lavanya Natarajan and Ishika Nag from Florida, Neel Moudgal from ...
- Amid spike in cases, EU to shortly approve first COVID antibody drugs - sourcesThe European Medicines Agency (EMA) will this week give the green light to the treatment developed by U.S. biotech firm Regeneron and Swiss...
- India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktailRegeneron and Roche's antibody cocktail has also received emergency use approval in India, and will be distributed by drugmaker Cipla. The ...
- Roche reports promising results from anti-Covid cocktailThe results of the Phase 3 trial showed that the combination of the antibodies casirivimab and imdevimab "reduced hospitalisation or death ...
- Canada pledges C$485 million in COVID-19 aid for other countriesThe money will enable the United Nations children's agency UNICEF to buy up to 3 million courses of antibody treatments once they are appro...
- United States scientists developing nasal spray to prevent COVID-19The idea is to use a weakened virus as a delivery truck to carry genetic instructions to cells within the nose and the throat, which will i...
- 2nd study testing a COVID-19 antibody drug has a setbackTests in animals suggest that antibody drugs work best when given early in infection to lower the amount of virus, he said. Once someone is...
- Eli Lilly antibody drug fails in a COVID-19 study; others go onIndependent monitors had paused enrolment in the study two weeks ago because of a possible safety issue. But on Monday, the National Instit...
- US regulators approve 1st treatment for EbolaThe Food and Drug Administration OK'd the drug developed by Regeneron Pharmaceuticals for treating adults and children with the Zaire Ebola...
- Sanofi and Regeneron's eczema drug gets FDA approvalThe FDA approved Dupixent (dupilumab), is the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.
Load More
